Coinheritance of Β-Thalassemia and Sickle Cell Anaemia in Southwestern Nigeria by Vincent, Osunkalu et al.





















BACKGROUND: Genes for haemoglobin S are found in high frequencies in Nigeria. However, there is 
little information on beta thalassemia in sickle cell anaemia in this population. The clinical presentation 
of HbS- β thalassemia is enormously variable, ranging from an asymptomatic state to a severe disorder 
similar to homozygous sickle cell disease. 
MATERIALS AND METHODS: Haemoglobin A2 and HbF were determined in sickle cell anaemia 
patients attending LAUTECH Teaching Hospital, Osogbo, by elution after electrophoresis and alkaline 
denaturation methods respectively. Haematological parameters were estimated using Sysmex KX-21N 
and percentage target cells using Leishman’s staining technique. 
RESULTS: Exactly 6% f the SCA patients were found to have elevated HbA2 (>3.3%) and HbF (>1.3%). 
These patients also had normal erythrocyte indices, increased platelet count, a significantly higher HCT 
and an increased % target cell. 
CONCLUSION: These findings confirm that the frequency of beta thalassaemia in sickle cell patients in 
Nigeria is higher than previously thought. It is therefore important to consider the possibility of this 
variant in patients with sickle cell anaemia since their course may differ from that of patients with 
homozygous sickle cell anaemia. 
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INTRODUCTION  
 
Beta-thalassemia (ß- thalassemia) is one of the 
most common genetic diseases which involve a 
diverse group of disorders of hemoglobin 
synthesis(1).This disorder occurs as a result of 
reduced output of the ß-chains of adult 
hemoglobin  and this results in reduced Hb in red 
blood cells (RBC), decreased RBC production and 
anemia(1,2).  
Beta -thalassemia which could be classified 
as beta thalassemia major (ßº), beta thalassemia 
minor (ß
+
) and beta thalassemia intermedia (2) is 
mostly caused by point mutations or small 
deletions within the ß-globin gene or its 
immediate flanking sequences (1). However, in 
each affected ethnic group, a few common 
mutations together with a variable number of rare 
mutations account for most of the cases (3). 
Beta-thalassemia is prevalent in 
Mediterranean countries, the Middle East, Central 
Asia, India, Southern China and the Far East as 
well as countries along the north coast of Africa 
and in South America. The highest carrier 
frequency is reported in Cyprus (14%) and 
Sardinia (10.3%) (4). However, its frequency in 
Africa is variable (5,6). Little is known about the 
occurrence and manifestations of thalassaemia 
trait in Nigeria because it is a rare condition, and 
its diagnosis is considerably more difficult 
especially in heterozygote subjects. It has also 
been shown from previous studies that the 
incidence of beta  thalassaemia gene in Africa
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has been variable (5,6). Sickle cell anemia (SCA) 
is a monogenic disease that characterizes the 
homozygous state of hemoglobin S (Hb S) (7). 
The complex pathophysiology includes anaemia, 
vaso occlusive crises, aplastic crises, sequestration 
crises and hemolytic crises all of which could be 
of acute or chronic course and may eventually lead 
to death (8). 
SCA is common in persons of African, 
Mediterranean, Middle Eastern and Indian 
ancestry, and in persons from the Caribbean and 
parts of Central and South America. Hpwever, 
they can be found in individuals of any ethnic 
background. In many regions of Africa, the 
prevalence of the Hb S gene mutation (Glu6Val) 
(i.e. HbS trait) is as high as 25% - 35%, with an 
estimated 15 million Africans affected by sickle 
cell disease (5,9).  
Sickle beta-thalassaemia (S/beta-
thalassaemia) is a condition, which results from 
coinheritance of a sickle cell gene and a beta-
thalassaemia gene. The clinical phenotype 
depends on the type of beta-thalassaemia gene 
(beta (+) or beta (o)) inherited. A definitive 
diagnosis is required in order to initiate early 
supportive treatment in patients with homozygous 
sickle cell disease (SS disease) and to define the 
later clinical course (10). 
The S/beta-thalassaemia can be diagnosed by 
family history, complete blood count and 
measurement of Hb A2 and Hb F levels (11). The 
clinical features of HbS- β thalassemia are 
tremendously variable, ranging from a completely 
asymptomatic state to a severe disorder similar to 
homozygous sickle cell disease depending on the 
inheritance of each gene (12). This heterogeneity 
is likely to be due to the presence of different β- 
thalassemia alleles or interaction with modulating 
genetic factors like associated α thalassemia 
and/or a gene for raised HbF production. 
Haemoglobin beta chain sequence analysis may be 
used to detect mutations associated with β-
thalassemias/hemoglobin variants. Gel 
electrophoresis or HPLC can differentiate these 
disorders from heterozygous carriers of the Hb S 
mutation (Hb AS, Hb SC and others) (13).  
There is little information on the 
coinheritance of beta-thalassemia in sickle cell  
anaemia patients in Nigeria. This study will 
therefore provide more information on the 
existence of coinheritance of beta-thalassemia in 
sickle cell anaemia in Southwest Nigeria by 
estimating the haemoglobin variants concentration 
and red cell indices which are diagnostic criteria 
for determining the presence of β-thalassemia 
genes using available methods.  
MATERIALS AND METHODS 
 
This is a cross sectional study in which a total 
of 100 sickle cell patients were recruited for 
the study.These patients comprised of 46 
males and 54 females attending haematology 
clinic of the Ladoke Akintola University 
Teaching Hospital (LTH), Osogbo, Osun State 
were recruited for period of six (6) months. 
Subjects in crises, pregnant women and those 
on the use of herbal medications were 
excluded from the study in order to prevent 
variations in HbF or HbA2 concentration 
which may be induced by physiological stress 
of pregnancy (14) or by the emerging 
unevaluated herbal constituent intake in this 
region (15). The sample size of 100 subjects 
recruited in this study was obtained using 
Thumb’s rule statistical formula (18). 
About 2.5ml of venous blood was collected 
in an ethylenediamine tetra acetic acid (EDTA) 
anticoagulated bottle (Becton Dickinson). 
Complete Blood Count which included the 
haematocrit (HCT), the red cell distribution width 
(RDW), the red cell indices (Mean Cell Volume 
(MCV), Mean Cell Haemoglobin (MCH), Mean 
Corpuscular Haemoglobin Concentration 
(MCHC)) and the absolute platelet count was 
determined using Sysmex KX-2 IN Autoanalyser 
(16). 
Haemoglobin F level was determined by 
Alkaline Denaturation Method.The method 
involve preparation of haemoglobincyanide 
solution which was treated with NaOH and 
saturated ammonium sulphate solution.The 
solution was then filtered and measured 
spectrophotometrically to determine the alkali 
resistant haemoglobin (Hb F) (17).In addition, the 
Haemoglobin A2 level was estimated using 
Elution from Cellulose acetate Method.This  is a  
process in which HbA2 was separated from HbA 
on cellulose acetate electrophoresis at pH8.9, 
eluted into buffer and the percentage calculated by 
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measuring the absorbance of the HbA2 eluate 
(6,18 ). 
The coexistence of elevated HbA2  (>3.5%) 
and HbF (>1%) was considered indicative of β- 
thalassemia trait (19).The Blood Film Appearance 
by Leishman’s Stain was used to determine the 
percentage target cells. 
 All analysis were performed with 
commercially available software (EPI Info version 
3.5.3.). Significance of differences and 
comparison of means between groups was 
determined using the independent t-test while Chi 
square was used to compare proportions. 





The 100 subjects comprised of 54 men and 46 
women. Their haematocrit ranged from 13.0 – 
36.9% with a mean haematocrit of 0.25 ± 
0.009L/L. The mean HbA2 among the subjects 
was 3.0 ± 0.8% with a range of 2.0–4.1%. 
Thirteen (13%) of the subjects had HbA2 values 
higher than 3.3% while 2 (23%) had HbA2 values 
greater than 3%. 
The mean HbF was 1.0 ± 0.6% with a range 
0.9–2.8%.Ten (10%) and 19% of the patients had 
HbF values greater than 1.3% and 1% 
respectively. The mean platelet count and 
percentage target cells were 329.19 ± 9.37 x10
6
/L 
and 14.31± 2.08% respectively.  
Six percent (6/100) of the subjects had both 
elevated HbA2 (>3.3) and HbF (>1.3) displaying a 
statistical significance at p<0.005 as represented in 
Table 1. These six subjects also had an increased 
mean % Target cells (27 vs.13.4 %, p=2.05x10
-5
), 
Platelet count (468.1 vs. 322.1 x10
6
/L, p=0.04), 
HCT (28.8 vs. 25.1%, p=0.05) and a weak band of 
HbA on electrophoresis compared with other SCA 
subjects. This is indicated in Table 2. 
 
Table 1: Cross tabulation of HbF versus HbA2 
 
                                                        HbF (%)                            Total            P-value 
                                               <1.3    >1.3 
                               <3.3    83(92.2)         4(40)             87 
HbA2 (%)                           0.0002 
                 >3.3    7(7.8)         6(60)               13 
Total                      90                10              100 
 
     
  Table 2: Differences between subjects with Sickle-Beta Thalassemia and Homozygous Sickle cell anaemia 
 
 
                                        HCT(L/L)     MCV(fl)      MCH(pg)   MCHC(g/dl)  PLT(10
6
/L)  %TC*   RDW 
HbF<1.3; HbA2<3.3(%) 
 (n=94)           0.25             77.21             24.20           31.24              322.10          13.40     54.10 
 
HbF>1.3; HbA2 >3.3(%) 





The clinical and hematologic features in HbS/β 
thalassemia inheritance are quite variable: some 
are severe while some are less significant. The 
clinical severity largely depends upon the nature 
of the β thalassemia mutations inherited. HbS/β 
thalassemias are classified as HbS/β
0
 thalassemia, 
having absence of HbA with a severe clinical 
course similar to homozygous Hb S disease and 
HbS/β
+
 thalassemia usually associated with 20-
30% of HbA with a milder clinical course (12). 
However, studies showed that HbS-β
+
 
thalassemia cases with the IVS 1-5 (G→C) or IVS 
II-745 mutation had low HbA levels (3–5%) 
which orchestrated the conclusion that this level of 
 
*%TC- Percentage Target Cells 





HbA does not influence the clinical expression of 
the disease compared to sickle cell disease in the 
community (20). This can be observed in this 
present study with the display of a weak band of 
HbA on electrophoresis. 
In addition, a study by Murkerjee et al 
indicated that the HbS/β
+
 thalassemia patients had 
quite variable clinical presentation.This could be 
partially explained by the association of α 
thalassemia (9/11) and XmnI polymorphism in 
HbF production, either in homozygous or 
heterozygous state(21). This findings was 
corroborated by an earlier study which  reported 
that sickle homozygous individuals from  
Maharashtra and Gujarat regions in Western India 
have shown that α thalassemia is the major 
modulator of the severity of the disease.This was 
because it was observed to be more prevalent 
among tribals with a milder disease than among 
nontribal with more severe manifestations (22). 
This study which showed that beta- 
thalassaemia trait in Nigeria is higher than 
previous thoughts was based on elevated HbA2 
and HbF levels as well as increased % target cells. 
Out of the 100 subjects in this study, six 
participants (comprising of four males and two 
females) currently managed as sickle cell anaemia 
were discovered to have increased HbF (>1.32%) 
and HbA2 (>3.32%) and the presence of a less 
significant concentration of HbA electrophoretic 
band. 
This was much higher than figures reported 
in a previous study (1.2%) which investigated the 
presence of β-thalassemia in sickle cell anaemia 
with increased level of HbF (>1.5%) and HbA2 
(>3.5%) in Benin, Nigeria (6). A similar study by 
Kotila et al in Ibadan, Nigeria, showed much 
higher figures of the population (25%) with 
increased HbF and HbA2 levels in healthy 
individuals (23).  
It was observed in this study that about a 
third of subjects with increased HbF (30%) were 
associated with increase in % target cell 
(>24%).This  corresponds with reports of several 
studies that target cells along with other 
poikilocytes are present in sickle cell anaemia and 
thalassemia although the precise percentage was 
not stated (24). Also, Omoti C.E in a similar study 
reported that peripheral blood film revealed the 
presence of target cells and occasional microcytes 
apart from the sickled cells (6).   
Elevated HbF compared with the red cell indices 
in this study indicated that the HbF does not have 
a significant effect on the red cell indices 
(P<0.05). This was observed by Beutler in 1990 
that individual values for MCV, MCH and MCHC 
occasionally overlapped with those in the normal 
population thus casting doubt on the adequacy of 
these criteria alone in identifying all cases of the 
heterozygous β-thalassaemia in SCA patients (25).  
Also, red cell indices in iron deficiency and 
alpha thalassaemia trait can give a similar picture 
as found in beta thalassaemia trait. It may 
therefore not be as informative in an environment 
in which the three pathologies exist concurrently 
(25). 
The mean difference in HbF and  HbA2 in 
this study shows that populations with higher HbF 
had a higher mean HbA2 (p=4.64 X10
-6
).This is 
concurrent with the conclusion of Omoti C.E. that 
the possibility of coinheritance of the S/beta 
thalassaemia gene occurs in about 1.2% of 
Nigerians with SCA (6). 
Populations with diagnostic features of S/β- 
thalassemia where compared with those subjects 
with sickle cell anaemia (Table 2), and statistically 
significant differences were observed in the mean 
% Target cells , Platelet count  and HCT with the 
mean value in S/β- thalassemia subjects higher 
than the homozygous sickle cell subjects. In 
contrast, a related study by Bashir et al, in North 
Jordan observed that total haemoglobin value was 
not significantly different (P greater than 0.05) in 
the two types of S/β-thalassemia (S/β° and S/β
+
) 
(26). However, platelet count was discovered to be  
usually normal in β-thalassemia, except in cases of 
splenomegaly (27). In addition, this significant 
increase in platelet count and HCT may be due to 
the interaction of the sickle cell gene with mild 
forms of ß-thalassaemia (S/ ß+thal) which may be  
quite innocuous compared with patients with 
haemoglobin S. 
Expectedly, the % target cells in S/β-
thalassemia doubled those for SCA in this study. 
This is justified by the outcome of a study which 
showd features of anisocytosis, microcytosis, 
reticulocytosis and high target cells in SCA 
subjects with β
+
-thalassemia gene (28).  
It should be noted that several methods are 
available for the quantification of HbA2, but 
electrophoresis is still the conservative method of 
choice ,nevertheless, it is slow and labour 
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intensive. HPLC which is a better and superior 
technology is very expensive in this locality.  
In conclusion, this study demonstrated that 
the coinheritance of beta-thalassaemia trait in 
sickle cell anaemia in Nigeria is about 6%. 
Therefore, it is important to consider beta- 
thalassaemia trait as a differential diagnosis in 
sickle cell anaemia patients who present with 
reduced or continuous haemolytic crises in this 
environment. 
Future studies using molecular methods on 
those classified as S/β-thalassemia patients is 
highly recommended.This will enable the 
determination of the exact type of mutation and 
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